Literature DB >> 36056172

Integrative multi-omics landscape of fluoxetine action across 27 brain regions reveals global increase in energy metabolism and region-specific chromatin remodelling.

Vibhor Kumar1, Jonathan Aow1, Naghmeh Rastegar2, Michelle Gek Liang Lim1, Nicholas O'Toole2, Nirmala Arul Rayan1, Edita Aliwarga1, Danusa Mar Arcego2, Hui Ting Grace Yeo1, Jen Yi Wong1, May Yin Lee1, Florian Schmidt1, Hajira Shreen Haja1, Wai Leong Tam1, Tie-Yuan Zhang2, Josie Diorio2, Christoph Anacker3, Rene Hen3, Carine Parent2, Michael J Meaney4,5,6,7, Shyam Prabhakar8.   

Abstract

Depression and anxiety are major global health burdens. Although SSRIs targeting the serotonergic system are prescribed over 200 million times annually, they have variable therapeutic efficacy and side effects, and mechanisms of action remain incompletely understood. Here, we comprehensively characterise the molecular landscape of gene regulatory changes associated with fluoxetine, a widely-used SSRI. We performed multimodal analysis of SSRI response in 27 mammalian brain regions using 310 bulk RNA-seq and H3K27ac ChIP-seq datasets, followed by in-depth characterisation of two hippocampal regions using single-cell RNA-seq (20 datasets). Remarkably, fluoxetine induced profound region-specific shifts in gene expression and chromatin state, including in the nucleus accumbens shell, locus coeruleus and septal areas, as well as in more well-studied regions such as the raphe and hippocampal dentate gyrus. Expression changes were strongly enriched at GWAS loci for depression and antidepressant drug response, stressing the relevance to human phenotypes. We observed differential expression at dozens of signalling receptors and pathways, many of which are previously unknown. Single-cell analysis revealed stark differences in fluoxetine response between the dorsal and ventral hippocampal dentate gyri, particularly in oligodendrocytes, mossy cells and inhibitory neurons. Across diverse brain regions, integrative omics analysis consistently suggested increased energy metabolism via oxidative phosphorylation and mitochondrial changes, which we corroborated in vitro; this may thus constitute a shared mechanism of action of fluoxetine. Similarly, we observed pervasive chromatin remodelling signatures across the brain. Our study reveals unexpected regional and cell type-specific heterogeneity in SSRI action, highlights under-studied brain regions that may play a major role in antidepressant response, and provides a rich resource of candidate cell types, genes, gene regulatory elements and pathways for mechanistic analysis and identifying new therapeutic targets for depression and anxiety.
© 2022. The Author(s).

Entities:  

Year:  2022        PMID: 36056172     DOI: 10.1038/s41380-022-01725-1

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   13.437


  101 in total

Review 1.  Efficacy and safety of antidepressants for children and adolescents.

Authors:  Jon N Jureidini; Christopher J Doecke; Peter R Mansfield; Michelle M Haby; David B Menkes; Anne L Tonkin
Journal:  BMJ       Date:  2004-04-10

2.  Educating Religious Leaders Increases Male Circumcision Rates in Tanzania.

Authors:  M J Friedrich
Journal:  JAMA       Date:  2017-04-18       Impact factor: 56.272

3.  Prescribing trends in psychotropic medications: primary care, psychiatry, and other medical specialties.

Authors:  H A Pincus; T L Tanielian; S C Marcus; M Olfson; D A Zarin; J Thompson; J Magno Zito
Journal:  JAMA       Date:  1998-02-18       Impact factor: 56.272

Review 4.  Therapeutic options in treatment-resistant depression.

Authors:  Eduard Vieta; Francesc Colom
Journal:  Ann Med       Date:  2011-05-31       Impact factor: 4.709

5.  Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.

Authors:  A John Rush; Madhukar H Trivedi; Stephen R Wisniewski; Andrew A Nierenberg; Jonathan W Stewart; Diane Warden; George Niederehe; Michael E Thase; Philip W Lavori; Barry D Lebowitz; Patrick J McGrath; Jerrold F Rosenbaum; Harold A Sackeim; David J Kupfer; James Luther; Maurizio Fava
Journal:  Am J Psychiatry       Date:  2006-11       Impact factor: 18.112

6.  Application of antidepressants in depression: A systematic review and meta-analysis.

Authors:  Ziqi Yuan; Zhenlei Chen; Maoqiang Xue; Jie Zhang; Lige Leng
Journal:  J Clin Neurosci       Date:  2020-08-19       Impact factor: 1.961

7.  Antidepressant use and risk of adverse outcomes in older people: population based cohort study.

Authors:  Carol Coupland; Paula Dhiman; Richard Morriss; Antony Arthur; Garry Barton; Julia Hippisley-Cox
Journal:  BMJ       Date:  2011-08-02

Review 8.  Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.

Authors:  Andrea Cipriani; Toshi A Furukawa; Georgia Salanti; Anna Chaimani; Lauren Z Atkinson; Yusuke Ogawa; Stefan Leucht; Henricus G Ruhe; Erick H Turner; Julian P T Higgins; Matthias Egger; Nozomi Takeshima; Yu Hayasaka; Hissei Imai; Kiyomi Shinohara; Aran Tajika; John P A Ioannidis; John R Geddes
Journal:  Lancet       Date:  2018-02-21       Impact factor: 79.321

9.  Selective serotonin reuptake inhibitors and suicidal behaviour: a population-based cohort study.

Authors:  Tyra Lagerberg; Seena Fazel; Arvid Sjölander; Clara Hellner; Paul Lichtenstein; Zheng Chang
Journal:  Neuropsychopharmacology       Date:  2021-09-24       Impact factor: 8.294

10.  National Prescription Patterns of Antidepressants in the Treatment of Adults With Major Depression in the US Between 1996 and 2015: A Population Representative Survey Based Analysis.

Authors:  Yan Luo; Yuki Kataoka; Edoardo G Ostinelli; Andrea Cipriani; Toshi A Furukawa
Journal:  Front Psychiatry       Date:  2020-02-14       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.